keyword
MENU ▼
Read by QxMD icon Read
search

Lymphoma Outcomes

keyword
https://www.readbyqxmd.com/read/30320386/intraocular-involvement-is-associated-with-a-high-risk-of-disease-relapse-in-primary-central-nervous-system-lymphoma
#1
Lin Zhuang, Jie Lai, Kun Chen, Tianling Ding, Yan Yuan, Yan Ma, Hui Kang, Zhiguang Lin, Ni Fan, Jingjing Ma, Qingchao Zeng, Xiaoping Xu, Qingping Wang, Bobin Chen
The aim of the present study was to prospectively evaluate the recurrence and survival outcome of primary central nervous system lymphoma (PCNSL) with intraocular involvement. For this purpose, a prospective cohort of 103 pathologically confirmed patients with PCNSL was enrolled in this study. Ophthalmologic examinations were performed both at diagnosis and during follow‑up. The patients with PCNSL with suspected intraocular involvement underwent vitrectomy for confirmation. Patients who presented with intraocular involvement either at diagnosis or during disease progression were allocated to the intraocular lymphoma (IOL) group...
October 11, 2018: Oncology Reports
https://www.readbyqxmd.com/read/30318297/acute-coronary-syndromes-in-patients-with-active-hematologic-malignancies-incidence-management-and-outcomes
#2
Jae Yoon Park, Wei Guo, Mohammed Al-Hijji, Abdallah El Sabbagh, Kebede H Begna, Thomas M Habermann, Thomas E Witzig, Bradley R Lewis, Amir Lerman, Joerg Herrmann
BACKGROUND: Cancer and cardiovascular diseases are the two leading causes of death in industrialized countries. Optimal management of life-threatening presentations of both of their diseases can pose significant challenges. The current study aimed to address the incidence, management, and outcome of acute coronary syndromes (ACS) in patients with active hematological malignancies. METHODS: This retrospective registry-based cohort study included adults with active leukemia or lymphoma who were hospitalized at Mayo Clinic Rochester from 01/01/2004 to 12/31/2014...
October 5, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/30317410/novel-immunotherapies-for-t-cell-lymphoma-and-leukemia
#3
REVIEW
Paola Ghione, Alison J Moskowitz, Nadia E K De Paola, Steven M Horwitz, Marco Ruella
PURPOSE OF REVIEW: Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia. RECENT FINDINGS: For T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity...
October 13, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/30315349/histamine-targets-myeloid-derived-suppressor-cells-and-improves-the-anti-tumor-efficacy-of-pd-1-pd-l1-checkpoint-blockade
#4
Hanna Grauers Wiktorin, Malin S Nilsson, Roberta Kiffin, Frida Ewald Sander, Brianna Lenox, Anna Rydström, Kristoffer Hellstrand, Anna Martner
Myeloid-derived suppressor cells (MDSCs) are immature monocytes and granulocytes that impede immune-mediated clearance of malignant cells by multiple mechanisms, including the formation of immunosuppressive reactive oxygen species (ROS) via the myeloid cell NADPH oxidase (NOX2). Histamine dihydrochloride (HDC), a NOX2 inhibitor, exerts anti-cancer efficacy in experimental tumor models but the detailed mechanisms are insufficiently understood. To determine effects of HDC on the MDSC compartment we utilized three murine cancer models known to entail accumulation of MDSC, i...
October 12, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/30315345/burden-of-illness-of-follicular-lymphoma-and-marginal-zone-lymphoma
#5
Neerav Monga, Loretta Nastoupil, Jamie Garside, Joan Quigley, Moira Hudson, Peter O'Donovan, Lori Parisi, Christoph Tapprich, Catherine Thieblemont
Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are two subtypes of indolent B cell non-Hodgkin lymphoma (NHL) that account for approximately 20% and 12% of all NHLs, respectively. FL and MZL are rare conditions with orphan disease designations. We conducted a comprehensive review of the burden of FL and MZL that encompasses the epidemiological, real world clinical, economic, and humanistic impact of these diseases globally. A targeted literature search identified 31 eligible studies for review. Epidemiological coverage was poor, with data obtained for studies from only seven countries...
October 13, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30315239/updated-results-from-the-phase-3-helios-study-of-ibrutinib-bendamustine-and-rituximab-in-relapsed-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma
#6
G Fraser, P Cramer, F Demirkan, R Santucci Silva, S Grosicki, A Pristupa, A Janssens, J Mayer, N L Bartlett, M-S Dilhuydy, H Pylypenko, J Loscertales, A Avigdor, S Rule, D Villa, O Samoilova, P Panagiotidis, A Goy, M A Pavlovsky, C Karlsson, M Hallek, M Mahler, M Salman, S Sun, C Phelps, S Balasubramanian, A Howes, A Chanan-Khan
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1-45.8). Investigator-assessed median progression-free survival (PFS) was not reached for ibrutinib+BR, versus 14...
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30314618/a-generic-model-for-follicular-lymphoma-predicting-cost-life-expectancy-and-quality-adjusted-life-year-using-uk-population-based-observational-data
#7
Han-I Wang, Eve Roman, Simon Crouch, Eline Aas, Cathy Burton, Russell Patmore, Alexandra Smith
OBJECTIVES: To use real-world data to develop a flexible generic decision model to predict cost, life expectancy, and quality-adjusted life-years (QALYs) for follicular lymphoma (FL) in the general patient population. METHODS: All patients newly diagnosed with FL in the UK's population-based Haematological Malignancy Research Network (www.hmrn.org) between 2004 and 2011 were followed until 2015 (N = 740). Treatment pathways, QALYs, and costs were incorporated into a discrete event simulation to reflect patient heterogeneity, including age and disease management...
October 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30314526/operative-r0-resection-of-diffuse-large-b-cell-lymphoma-of-the-pelvis-a-case-report
#8
Valerie Wienerroither, Martin Sauerschnig, Christine Beham-Schmid, Erwin Mathew, Azab El-Shabrawi, Hans-Jörg Mischinger, Peter Kornprat
BACKGROUND: Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma with or without involvement of extranodal sites. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy represents the current standard therapy, achieving a rather dissatisfying outcome in approximately 30-40% of all cases. CASE PRESENTATION: We present the case of a 43-year-old Austrian woman with an incidentally detected large pelvic mass which was diagnosed as diffuse large B-cell lymphoma...
October 13, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/30313065/richter-s-syndrome-of-the-central-nervous-system-diagnosed-concurrently-with-chronic-lymphocytic-leukaemia-a-case-report-and-literature-review
#9
Liye Xu, Jin Cheng Song, Xiu Hua Sun, Zi Fen Gao, Li Lv, Jie Zhu
RATIONALE: Central nervous system (CNS) infiltration of Richter's syndrome (RS) is rare and only a few cases were discussed. Of these published cases, either they were accompanied with lymph node involvement or with a history of chronic lymphocytic leukemia (CLL). To our knowledge, this is the first published case of RS of the brain and meninges diagnosed concurrently with CLL in the absence of any evidence of lymphoma outside of the CNS. PATIENT CONCERNS: A 67-year-old female presented with slurred speech, headache, and left-sided hemiparesis...
October 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/30312133/risk-factors-for-transformation-to-higher-grade-lymphoma-and-its-impact-on-survival-in-a-large-cohort-of-patients-with-marginal-zone-lymphoma-from-a-single-institution
#10
Juan Pablo Alderuccio, Wei Zhao, Amrita Desai, Nicolas Gallastegui, Jeremy Ramdial, Erik Kimble, Macarena I de la Fuente, Joseph D Rosenblatt, Jennifer R Chapman, Francisco Vega, Isildinha M Reis, Izidore S Lossos
PURPOSE: Given the paucity of data on higher-grade transformation (HGT) to aggressive lymphoma in patients with marginal zone lymphoma (MZL), we report on a large cohort of patients, identify risk factors, and determine HGT impact on overall survival (OS). METHODS: We analyzed 453 patients with biopsy-proven MZL seen at our institution between 1995 and 2016. Kaplan-Meier, Cox proportional hazards regression, and competing risk methods were used in analyses of time-to-event outcomes...
October 12, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30311626/incidence-risk-factors-and-outcomes-of-malignancies-after-kidney-transplantation-in-singapore-a-12-year-experience
#11
Su Hooi Teo, Kian-Guan Lee, Gek Hsiang Lim, Si Xuan Koo, Maria Erika Ramirez, Khuan Yew Chow, Terence Kee
INTRODUCTION: Data on post-kidney transplantation (KTX) malignancy is limited in our region, leading to challenges in the care of renal allograft recipients. We aimed to examine the epidemiology, risk factors and outcomes of post-KTX patients. METHODS: A retrospective cohort study was conducted of 491 patients who underwent KTX from 1 January 2000 to 31 December 2011. Data linkage analysis was done between our centre and the National Registry of Disease Office to determine the standardised incidence ratio (SIR), standardised mortality ratio (SMR) and risk factors for malignancy after KTX...
October 10, 2018: Singapore Medical Journal
https://www.readbyqxmd.com/read/30310985/validation-of-the-marginal-zone-lymphoma-international-prognostic-index
#12
Joohyun Hong, Junhun Cho, Young Hye Ko, Seok Jin Kim, Won Seog Kim
The Marginal Zone Lymphoma International Prognostic Index (MALT-IPI) was recently developed for use in patients with mucosa-associated lymphoid tissue (MALT) lymphoma based on age, serum lactate dehydrogenase level, and Ann Arbor stage. In this study, we aimed to validate the MALT-IPI. A total of 455 MALT lymphoma patients were included in this study from between January 2005 and February 2017. Event-free survival (EFS), progression-free survival (PFS), cause-specific survival (CSS), and overall survival (OS) were the primary outcomes...
October 11, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30310784/clinical-features-and-survival-outcomes-of-patients-with-lymphoplasmacytic-lymphoma-including-non-igm-type-in-korea-a-single-center-experience
#13
Jihoon Kang, Jung Yong Hong, Cheolwon Suh
Background: The incidence of lymphoplasmacytic lymphoma (LPL) is lower in Asian than in Western populations. Few studies have described the clinical features and treatment outcomes of patients with LPL, including non-IgM LPL, in East Asia. Methods: We retrospectively analyzed patients diagnosed with LPL at Asan Medical Center between January 2001 and March 2016. We evaluated the clinical features and survival outcomes of patients with LPL and non-IgM LPL and compared these data with those of patients with LPL/Waldenström's macroglobulinemia (WM)...
September 2018: Blood Research
https://www.readbyqxmd.com/read/30309758/prognostic-value-of-end-of-induction-pet-response-after-first-line-immunochemotherapy-for-follicular-lymphoma-gallium-secondary-analysis-of-a-randomised-phase-3-trial
#14
Judith Trotman, Sally F Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter R Fingerle-Rowson, Jiawen Zhu, Tina Nielsen, Deniz Sahin, Wolfgang Hiddemann, Robert E Marcus, Andrew Davies
BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET-CT responses after first-line immunochemotherapy in the GALLIUM study. METHODS: GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1-3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment...
October 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30307902/intravenous-immunoglobulin-gamma-ivig-versus-ivig-plus-infliximab-in-young-children-with-kawasaki-disease
#15
Chun-Ling Han, Suo-Lin Zhao
BACKGROUND Kawasaki disease (KD) is a serious disease characterized by systemic lesions of the skin and mucous membranes, as well as lymphomas and vascular inflammation. KD threatens the health and lives of children, especially young ones. Here, we compared the therapeutic effects of single intravenous immunoglobulin gamma (IVIG) vs. a combination of IVIG and infliximab in young children with Kawasaki disease (KD). MATERIAL AND METHODS A total of 154 children with KD, younger than 5 years old, were enrolled in the study from January 2013 to January 2017...
October 11, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/30307529/dissection-of-dlbcl-microenvironment-provides-a-gene-expression-based-predictor-of-survival-applicable-to-formalin-fixed-paraffin-embedded-tissue
#16
S Ciavarella, M C Vegliante, M Fabbri, S De Summa, F Melle, G Motta, V De Iuliis, G Opinto, A Enjuanes, S Rega, A Gulino, C Agostinelli, A Scattone, S Tommasi, A Mangia, F Mele, G Simone, A F Zito, G Ingravallo, U Vitolo, A Chiappella, C Tarella, A M Gianni, A Rambaldi, P L Zinzani, B Casadei, E Derenzini, G Loseto, A Pileri, V Tabanelli, S Fiori, A Rivas-Delgado, A López-Guillermo, T Venesio, A Sapino, E Campo, C Tripodo, A Guarini, S A Pileri
Background: Gene-expression-profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of prognostic stromal signatures remains limited. Patients and methods: Here, we applied the computational method CIBERSORT to generate a 1,028-gene matrix incorporating signatures of 17 immune and stromal cytotypes. Then, we performed a deconvolution on publicly available GEP data of 482 untreated DLBCLs to reveal associations between clinical outcomes and proportions of putative tumor-infiltrating cell types...
October 11, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30307363/successful-implementation-of-genomically-based-treatment-of-chemotherapy-refractory-peripheral-t-cell-lymphoma-ptcl
#17
Natalie Galanina, Razelle Kurzrock
BACKGROUND: The treatment of peripheral T-cell lymphoma (PTCL) after failure of standard therapy represents a significant clinical challenge as the best approach has not been defined. The outcomes of patients with peripheral T-cell lymphoma (PTCL) after relapse, in the absence of hematopoietic stem-cell transplantation, are poor with median overall survival is less than six months. Thus, relapsed/refractory PTCL presents an area of unmet medical need. CASE PRESENTATION: Herein, we report an 84-year old woman with stage IV PTCL with extensive involvement of the bowel and abdominal pain...
October 11, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/30306208/myc-bcl2-and-bcl6-rearrangements-in-primary-central-nervous-system-lymphoma-of-large-b-cell-type
#18
Anahita Nosrati, Ahmad Monabati, Alireza Sadeghipour, Fatemeh Radmanesh, Akbar Safaei, Sajjadeh Movahedinia
Primary central nervous system lymphoma (PCNSL) is a rare specific subtype of non-Hodgkin lymphoma limited to the brain, leptomeninges, spinal cord, or eyes without any systemic presentation and relapse which mostly takes place in CNS. In more than 95% of patients, it is of diffuse large B cell lymphoma (DLBCL) type. Categorizing PCNSL to germinal center cell like or activated B cell like, as we usually do for DLBCL NOS, may not be applicable for predicting outcome. Possible prognostic significance of MYC, BCL2, and/or BCL6 rearrangements may be important given what we know about their impact in systemic DLBCL, but we have limited knowledge about the status of double or triple hit molecular changes in PCNSL...
October 11, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30305939/bet-bromodomain-inhibitor-birabresib-in-mantle-cell-lymphoma-in-vivo-activity-and-identification-of-novel-combinations-to-overcome-adaptive-resistance
#19
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, Luciano Cascione, Valentina Restelli, Alberto Jesus Arribas, Filippo Spriano, Andrea Rinaldi, Afua Adjeiwaa Mensah, Ivo Kwee, Maurilio Ponzoni, Emanuele Zucca, Laura Carrassa, Maria E Riveiro, Keyvan Rezai, Anastasios Stathis, Esteban Cvitkovic, Francesco Bertoni
Background: The outcome of patients affected by mantle cell lymphoma (MCL) has improved in recent years, but there is still a need for novel treatment strategies for these patients. Human cancers, including MCL, present recurrent alterations in genes that encode transcription machinery proteins and of proteins involved in regulating chromatin structure, providing the rationale to pharmacologically target epigenetic proteins. The Bromodomain and Extra Terminal domain (BET) family proteins act as transcriptional regulators of key signalling pathways including those sustaining cell viability...
2018: ESMO Open
https://www.readbyqxmd.com/read/30305860/primary-diffuse-large-b-cell-non-hodgkin-s-lymphoma-of-the-breast-a-case-report-and-review-of-the-literature
#20
Ola A Harb, Safa A Balata, Hassan Ashour, Eman Eltokhy, Loay M Gertallah, Rham Z Ahmed, Ali M Hassanin
Primary breast lymphoma (PBL) is considered a rare clinical entity forming about 0.4%-0.5% of all breast tumors. In this report we have presented a case of PBL in a 56-year-old female complaining of a mass in the upper medial quadrant of the breast. PBL suspicion of our case was made by breast radiology and the sure diagnosis was reached by the immunohistochemistry results; CD (cluster of differentiation) 20: was diffusely positive; Pan-CK (pan-cytokeratin): was diffusely negative in tumor cells. Hence, the case was finally diagnosed as a primary breast a primary breast diffuse large B-cell non-Hodgkin's lymphoma of lymphoma...
January 2019: Radiology Case Reports
keyword
keyword
162410
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"